KPV Dosage Chart
Oral and subcutaneous protocols for KPV, the C-terminal tripeptide of α-MSH, with stacking notes for gut and inflammatory uses.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
KPV is the C-terminal tripeptide fragment of α-MSH (alpha-melanocyte-stimulating hormone), studied primarily in animal models for IBD, skin inflammation, and antimicrobial activity. Human trial data at consumer doses is essentially absent — protocols are extrapolated from preclinical pharmacology and clinician practice in 503A/503B compounding.
KPV at a Glance
| Typical dose range | 250–500 mcg/day |
|---|---|
| Route | Oral capsule (most common for gut) or subcutaneous injection |
| Frequency | Once or twice daily |
| Cycle length | 4–6 weeks on, 2–4 weeks off |
| FDA status | Not FDA-approved. Compounded; preclinical data only at consumer-relevant doses. |
| Common uses | IBD/IBS adjunct, gut inflammation, eczema/skin (topical) |
KPV Reconstitution Chart
How vial size, bacteriostatic water volume, and insulin-syringe units convert for KPV. Use this to translate a prescribed mcg or mg dose into a syringe measurement.
| Vial size | Bac water | Concentration | Dose → insulin-syringe units (U-100) |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL (250 mcg per 0.1 mL) |
|
| 10 mg | 5 mL | 2 mg/mL (200 mcg per 0.1 mL) |
|
KPV Dosing by Use Case
Commonly cited protocols vary by what KPV is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| IBD / IBS / gut inflammation (oral) | 250–500 mcg | 1–2× daily oral | 4–6 weeks | Often combined with oral BPC-157 for gut-focused stacks. |
| Systemic anti-inflammatory (subQ) | 250 mcg | Once daily subQ | 4–6 weeks | Less common than oral; injectable use is practitioner-driven. |
| Topical skin (eczema, psoriasis adjunct) | Compounded cream | 1–2× daily topical | 4–8 weeks | Compounded preparations only — not a standard pharmacy item. |
Stacking KPV
KPV is most commonly stacked with oral BPC-157 for gut conditions — the two are seen as complementary because BPC-157 supports mucosal healing while KPV provides anti-inflammatory tone. Both can be taken oral, simplifying compliance.
KPV is reported to be well-tolerated in preclinical work, but human safety data at consumer doses is essentially absent.
- •Side effects in practice are minimally reported, likely because the peptide is short-acting and used at low doses.
- •No formal human MTD or long-term safety data exists.
- •Theoretically immunomodulatory — caution in patients on immunosuppressants or with autoimmune disease.
- •Not FDA-approved for any indication.
- •Pregnancy or breastfeeding
- •Active immunosuppression therapy (consult prescriber)
KPV Dosing FAQ
Oral is the standard for gut indications because the peptide acts on intestinal tissue directly and survives oral administration as a tripeptide. Injectable is reserved for systemic inflammatory uses.
KPV provides anti-inflammatory and antimicrobial activity via α-MSH receptor pathways. BPC-157 supports mucosal repair, angiogenesis, and tissue remodeling. The two are seen as mechanistically complementary, which is why they're often stacked for gut conditions.
KPV is available through 503A/503B compounding pharmacies with a provider prescription. Direct-to-consumer 'research peptide' sales exist online but are not legal channels for human use.
Sources
Related Dosage Charts
Want the full KPV guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for KPV therapy.
See KPV guideMedical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.